Beta Blockers May Not Benefit Many Heart Attack Patients With Preserved Heart Function
Similar Articles
Injectable Biomaterial Shows Promise for Repairing Heart Attack Damage
GLP-1 Receptor Agonists Reduce Cardiovascular Risk Across Patient Groups
Anti-Amyloid Drugs Show Limited Benefit for Early Alzheimer's, Carry Side Effects
Structured Mediterranean Diet Program Reduces Type 2 Diabetes Risk by 31% in Major Trial
Existing Drugs Show Promise in Reversing Fatty Liver Disease in Animal Studies
A major international trial has found that beta blockers, a standard medication for decades, do not significantly reduce the risk of death, repeat heart attack, or heart failure hospitalization for patients with preserved heart function following a heart attack. The findings, presented at a major cardiology congress, challenge a routine practice affecting over 80% of patients with uncomplicated heart attacks. The study was conducted without pharmaceutical industry funding.
Facts First
- Beta blockers did not significantly reduce death, repeat heart attack, or heart failure hospitalization in heart attack patients with preserved heart function over nearly four years.
- A substudy found women with normal heart function had a higher risk of adverse events when taking beta blockers compared to those who did not, an increased risk not observed in men.
- More than 80 percent of patients with uncomplicated heart attacks are currently prescribed beta blockers upon hospital discharge.
- The REBOOT trial enrolled 8,505 patients from 109 hospitals in Spain and Italy, providing a large-scale, independent assessment.
- Recent trials have presented mixed evidence, with some supporting continued use in patients with mildly reduced heart function.
What Happened
The REBOOT trial investigated the long-term use of beta blockers after a heart attack. It enrolled 8,505 patients from Spain and Italy who were randomly assigned to receive beta blockers or avoid them after hospital discharge while receiving standard care. After a median follow-up of almost four years, the results, presented at the European Society of Cardiology Congress and published in The New England Journal of Medicine, showed no significant reduction in death, repeat heart attack, or hospitalization for heart failure from beta blockers in patients with preserved heart function.
Why this Matters to You
If you or a loved one has a heart attack with preserved heart function, this research suggests the routine prescription of beta blockers may not provide the expected protective benefit against future major cardiac events. This could lead to discussions with your doctor about whether to continue a medication that can cause side effects like fatigue, low heart rate, and sexual dysfunction. For women with normal heart function, the study data indicates they might face a higher risk of adverse outcomes when taking these drugs.
What's Next
Clinical practice guidelines for post-heart attack care may be updated to reflect this new evidence, potentially leading to more personalized treatment decisions. Doctors are likely to more carefully evaluate a patient's specific heart function before prescribing beta blockers long-term. Further research is needed to clarify the risks and benefits for different patient subgroups, particularly women, and to confirm the findings of other recent trials which suggest patients with mildly reduced heart function may still benefit from the medication.